Bio-Techne has made a strategic investment in Astute Medical, which already counts corporates Fosun, Johnson & Johnson and Kaiser Permanente as shareholders.
US-based diagnostics technology developer Astute Medical has received a $43m commitment from a consortium including life sciences company Bio-Techne Corporation as part of a strategic partnership agreement.
Unnamed existing backers also participated in the round, which increased Astute Medical’s total funding to approximately $158m in funding to date.
Founded in 2007, Astute Medical’s lead product, Nephrocheck, is a test that is able to assess the risk of moderate to severe acute kidney injury in hospitalised patients. The test has achieved regulatory…
